Drugs / Decitabine-cedazuridine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07710534 | Sep 2026 → Sep 2031 expected | acute myeloid leukemia, myelodysplastic syndrome | Virginia Commonwealth University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Decitabine-cedazuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710534 ↗ |
| Known as | DEC-C | “Decitabine-cedazuridine (DEC-C) dosage per protocol taken by mouth once weekly” NCT07710534 ↗ |